Skip to main content

Table 2 Eligibility to the procedure of CRS with HIPEC

From: Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons

Factors that interrupt the right treatment of CRS with HIPEC N (%)  
Old age 7 (21)  
ECOG performance status 18 (53)  
Invasion to numerous mesenteries 34 (100)  
 Cancer that invade multiple organs (more than 3 organs) 5 (15)  
 Cancer that invade more than 3 parts of liver parenchyma 10 (29)  
 Cancer that invade the portal vein 16 (47)  
 Cancer that invade a frozen pelvis 7 (21)  
 Ureteral stricture 2 (6)  
 Others 2 (6)  
The number of factors that interrupt the right treatment of CRS with HIPEC Mean (SD) P
Surgeon’s age (n)
 < 50 (23) 2.41 ± 1.43  
 > 50 (11) 2.81 ± 1.60 0.352
Volume of medical institution (n)
 University hospital (23) 2.42 ± 1.43  
 Other hospital (11) 2.81 ± 1.60 0.488
Experience number of PSM (n)
 < 50 (20) 2.26 ± 1.49  
 < 50 (14) 3.21 ± 1.31 0.079